Sanaz Gabery
Overview
Explore the profile of Sanaz Gabery including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
20
Citations
539
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Wang W, Bain S, Bian F, Chen R, Gabery S, Huang S, et al.
Diabetologia
. 2024 Jul;
67(9):1783-1799.
PMID: 38985162
Aims/hypothesis: The aim of this study was to evaluate the efficacy and safety of oral semaglutide monotherapy vs placebo in a predominantly Chinese population with type 2 diabetes insufficiently controlled...
2.
Ji L, Agesen R, Bain S, Fu F, Gabery S, Geng J, et al.
Diabetologia
. 2024 Jul;
67(9):1800-1816.
PMID: 38985161
Aims/hypothesis: The aim of this study was to assess the efficacy and safety of oral semaglutide vs sitagliptin in a predominantly Chinese population with type 2 diabetes inadequately controlled with...
3.
Aroda V, Aberle J, Bardtrum L, Christiansen E, Knop F, Gabery S, et al.
Lancet
. 2023 Jun;
402(10403):693-704.
PMID: 37385279
Background: Once-daily oral semaglutide is an effective type 2 diabetes treatment. We aimed to investigate a new formulation of oral semaglutide at higher investigational doses versus the approved 14 mg...
4.
Bergh S, Gabery S, Tonetto S, Kirik D, Petersen A, Cheong R
Neuropathol Appl Neurobiol
. 2023 Feb;
49(2):e12891.
PMID: 36776123
Background: Early non-motor features including anxiety, depression and altered social cognition are present in Huntington's disease (HD). The underlying neurobiological mechanisms are not known. Oxytocin (OXT) is involved in the...
5.
Bergh S, Cheong R, Petersen A, Gabery S
Front Mol Neurosci
. 2022 Oct;
15:984317.
PMID: 36187357
Neurodegenerative disorders (NDDs) such as Huntington's disease (HD) and the spectrum of amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD) are characterized by progressive loss of selectively vulnerable populations of...
6.
Gabery S, Kwa J, Cheong R, Baldo B, Bardile C, Tan B, et al.
Acta Neuropathol
. 2021 Aug;
142(5):791-806.
PMID: 34448021
Huntington disease (HD) is a fatal neurodegenerative disorder caused by an expanded CAG repeat in the huntingtin (HTT) gene. The typical motor symptoms have been associated with basal ganglia pathology....
7.
Gabery S, Ahmed R, Caga J, Kiernan M, Halliday G, Petersen A
Neuropathol Appl Neurobiol
. 2021 Mar;
47(7):979-989.
PMID: 33755993
Aims: To determine the underlying cellular changes and clinical correlates associated with pathology of the hypothalamus in amyotrophic lateral sclerosis (ALS), as hypothalamic atrophy occurs in the preclinical phase of...
8.
Fjalldal S, Rylander L, van Westen D, Holmer H, Follin C, Gabery S, et al.
Clin Endocrinol (Oxf)
. 2020 Aug;
94(1):48-57.
PMID: 32762072
Context: White matter lesions (WML) are caused by obstruction of small cerebral vessels associated with stroke risk. Craniopharyngioma (CP) patients suffer from increased cerebrovascular mortality. Objective: To investigate the effect...
9.
Gabery S, Salinas C, Paulsen S, Ahnfelt-Ronne J, Alanentalo T, Baquero A, et al.
JCI Insight
. 2020 Mar;
5(6).
PMID: 32213703
Semaglutide, a glucagon-like peptide 1 (GLP-1) analog, induces weight loss, lowers glucose levels, and reduces cardiovascular risk in patients with diabetes. Mechanistic preclinical studies suggest weight loss is mediated through...
10.
Cheong R, Gabery S, Petersen A
J Huntingtons Dis
. 2019 Oct;
8(4):375-391.
PMID: 31594240
Huntington's disease (HD) is a fatal genetic neurodegenerative disorder. It has mainly been considered a movement disorder with cognitive symptoms and these features have been associated with pathology of the...